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A B S T R A C T
 
Background: Sub-optimal levels of vitamin D have been found to be highly prevalent in all age 
groups, with epidemiologic studies demonstrating a link between vitamin D deficiency and 
disease susceptibility, such as infection and cancer, and mortality rates. In adult transplant 
patients, it has been suggested that the immunomodulatory properties of vitamin D may 
have an important role in the prevention and treatment of graft-versus-host disease.
Objective: The objective of this study was to assess serum 25-hydroxyvitamin D levels of 
children and adolescents submitted to allogeneic hematopoietic stem cell transplantation.
Methods: Serum 25-hydroxyvitamin D levels of 66 patients, aged 4-20 years, were assessed 
at three stages: before hospitalization for hematopoietic stem cell transplantation and at 
30 and 180 days after hematopoietic stem cell transplantation. The control group consisted 
of 25 healthy children.
Results: At the pre-hematopoietic stem cell transplantation stage, patients had lower levels 
of 25-hydroxyvitamin D compared to controls (25.7 ± 12.3 ng/mL vs. 31.9 ± 9.9 ng/mL; p-value 
= 0.01), and a higher prevalence of 25-hydroxyvitamin D deficiency (32% vs. 8%; p-value 
= 0.01). Prevalence increased significantly after hematopoietic stem cell transplantation 
(p-value = 0.01) with half of the patients having vitamin D deficiency at 180 days after 
transplantation. At this stage, mean serum 25-hydroxyvitamin D levels were 20.9 ± 10.9 ng/mL, 
a significant decline in relation to baseline (p-value = 0.01). No correlation was found 
between 25-hydroxyvitamin D levels and vitamin D intake, graft-versus-host disease, 
corticoid use or survival rates.
Conclusion: Low levels of 25-hydroxyvitamin D were detected even before hematopoietic 
stem cell transplantation and were significantly lower at 180 days after hematopoietic stem 
cell transplantation, thus recommending vitamin D supplementation for children and 
adolescents submitted to hematopoietic stem cell transplantation.
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Introduction
Hematopoietic stem cell transplantation (HSCT) is a 
recommended procedure for the treatment of both benign 
and malignant hematologic diseases. It has been increasingly 
possible to reduce the number and the severity of complications 
associated with this procedure, and consequently, a growing 
number of patients have achieved long-term survival.1
Sub-optimal levels of vitamin D have been found to be 
highly prevalent in all age groups, with epidemiologic studies 
demonstrating a link between vitamin D status and disease 
susceptibility, such as infection and cancer, and mortality 
rates.2 Vitamin D deficiency is known to lead to rickets, 
osteomalacia and secondary hyperparathyroidism, muscle 
weakness and myalgia, all factors that accelerate bone mass 
loss and increase the risk for falls and fractures.3,4 However, 
besides its well-established role in the musculoskeletal 
physiology, activated vitamin D has been implicated in several 
other physiological functions in the body. These include anti-
carcinogenic properties, protection against cardiovascular 
disease, immune response regulation and auto-immune 
disease suppression through the ability of 1,25(OH)2D to 
modulate T lymphocyte proliferation and function.5-7
The prevalence of vitamin D deficiency has not been 
widely investigated in children submitted to HSCT. In adult 
patients receiving allogeneic HSCT, it has been suggested that 
the immunomodulatory properties of vitamin D may have 
an important role in the prevention and treatment of graft-
versus-host disease (GVHD), the leading cause of morbidity 
and mortality in this procedure.8,9 Patients unresponsive to 
corticosteroid treatment may experience milder GVHD effects 
after correction of vitamin D deficiency.9,10 Thus, the objective 
of the present study was to assess the vitamin D status of 
children and adolescents before and after allogeneic HSCT, 
and its correlation with GVHD incidence and mortality, 180 
days post HSCT.
Methods
All patients from four to 20 years of age submitted to 
allogeneic HSCT between August 2006 and September 
2008 at the Bone Marrow Transplantation Unit of our 
University Hospital were included in the study. Patients 
with osteometabolic disorders prior to HSCT were excluded. 
Patients were evaluated at three stages: before hospitalization 
for HSCT, and at 30 and 180 days after HSCT. The control group 
consisted of 25 healthy children recruited among children of 
employees of the University Hospital, matched for gender, 
age, race and body mass index (BMI) with the study group. 
Dietary vitamin D intake was assessed through an interview 
conducted by a registered dietician, of a 24-hour recall and 
food frequency questionnaire. Dietary intakes were considered 
adequate when they equaled or surpassed 85% of the dietary 
reference intake, which recommends a daily intake of 200 IU 
for the 4-20 year age group.11 Patients were interviewed about 
their daily sun exposure and personal history of fractures and 
family history of osteoporosis. Sun exposure was defined as 
‘low’ when the child had a recreational unprotected exposure 
of arms and legs of less than 15 minutes per day and less than 
three times a week;  ‘high’ when the exposure was at least 30 
minutes per day and five times per week; and ‘intermediate’ 
when between the aforementioned criteria.12 This study was 
approved by the Ethics Committee of the Hospital das Clinicas 
of the Universidade Federal do Paraná (UFPR) and all patients 
gave informed consent to participate in the study. 
Serum 25-hydroxyvitamin D [25(OH)D] concentrations 
were measured by chemiluminescence (Liaison kit, Diasorin, 
Stillwater, MN) at all visits. The following values were used 
to classify vitamin D status: vitamin D deficiency for values 
of 20  ng/mL or less; vitamin D insufficiency for values 
between 20.1 and 29.9  ng/mL, and normal state (vitamin D 
sufficiency) for values of 30 ng/mL or above.3 Blood samples 
were frozen and stored, and serum 25(OH)D concentrations 
were measured at the end of the study period. 
Patients were from different regions of Brazil, from places 
with different incidences of solar radiation, in latitudes 
between -30° to -5°. Hence, patients with low levels of vitamin 
D did not receive supplementation, since vitamin D status 
assessment is still not part of our center’s HSCT protocol. 
Statistical analysis
Values are presented as mean ± standard deviation (SD), 
except when otherwise stated. Differences between patients 
and controls for continuous variables were tested using an 
unpaired Student’s t-test or Mann-Whitney test according 
to the characteristics of the data distribution. Differences for 
categorical variables were analyzed with the chi-square and 
Fisher’s tests. Correlations were sought using the Pearson and 
Spearman coefficients for variables of normal and abnormal 
distributions, respectively. For all analyses, a two-sided p-value 
< 0.05 was considered to indicate statistical significance.
Results
Eighty children and adolescents were submitted to allogeneic 
HSCT in our institution during the study period. Fourteen were 
not included in the final analysis because they did not fulfill 
the inclusion criteria or they met the exclusion criteria. A total 
of 66 patients (38 boys and 28 girls aged 10 ± 4.1 years) were 
included in the study, and 15 of them (23%) died within the 
6-month period following HSCT. As shown in Table 1, unrelated 
and related allogeneic HSCT was performed in 55% and 45% of 
the patients, respectively. The diagnosis was a non-malignant 
disease in 67% of the patients, including Fanconi anemia (35%), 
severe aplastic anemia (15%), Wiskott-Aldrich syndrome (9%) 
and adrenoleukodystrophy (8%), and a malignant disease in 
33% of the group, including acute lymphocytic leukemia (14%), 
acute myeloid leukemia (9%), myelodysplasia (6%) and chronic 
myeloid leukemia (5%). Sixteen patients (25%) received a 
treatment scheme along with total body radiotherapy during 
the pre-transplantation conditioning stage, and 11 patients 
(17%) received corticosteroids for immunoprophylaxis of 
GVHD. Previous fractures were reported by eight patients (12%) 
and a family history of osteoporosis was identified in 14 (26%). 
In relation to their sun exposure before transplantation, eight 
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(12%) patients were classified as having low sun exposure, 
40 (61%) as intermediate and 18 (27%) as high exposure. 
Post-HSCT, all patients were instructed to refrain from sun 
exposure by their physician. 
At baseline, suboptimal 25(OH)D levels were observed in the 
majority of patients and controls, with vitamin D insufficiency 
or deficiency present in 47 (71%) of patients and in 13 (52%) 
controls. The mean serum 25(OH)D levels of the patients 
before HSCT was 25.7 ± 12.3 ng/mL, a value significantly lower 
than the mean levels of 31.9 ± 9.9 ng/mL found in the control 
group (p-value = 0.01; Figure 1). In addition, as shown in Table 
2, the prevalence of vitamin D deficiency was significantly 
higher in patients compared to controls (32% vs. 8% p-value = 
0.01). Dietary vitamin D intake was similar between the study 
groups (230.4 ± 110.8 IU/day in the patients vs. 196.8 ± 95.6 IU/
day in the controls); inadequate intakes were found in 18 
patients (27%) and nine controls (36%).
After HSCT, 24 patients (36%) developed either acute 
or chronic forms of GVHD (20 had acute GVHD, four had 
chronic GVHD and eight had both acute and chronic GVHD), 
and 33 patients (50%) received corticosteroids at an average 
cumulative dose of 105.0 ± 63.5 mg/kg body weight (0.97 ± 0.42 
mg/kg/day) of prednisone. There were no significant differences 
in serum 25(OH)D levels between patients with or without 
GVHD (20.2 ± 11.9 ng/mL vs. 20.5 ± 11.1 ng/mL, respectively), 
between those receiving or not receiving corticosteroids (21.6 
± 12.9 vs. 18.5 ± 13.0 ng/mL, respectively), or in the prevalence 
of vitamin D deficiency or insufficiency pre-HSCT in patients 
who developed GVHD. Median length of hospital stay was 36 
days (range: 22 to 137 days; mean: 45.4 days), during which 
all patients received a daily vitamin D dose of 400 to 800 
IU in accordance with the medical protocol of preventive 
vitamin supplementation. After discharge, 39 patients (59%) 
received vitamin D supplements (as part of the multivitamin 
supplementation scheme post HSCT) for an average of 140 ± 
55 days; six patients (9%) received a daily dose of more than 
1200 IU of vitamin D, and 33 (50%) received between 400 to 
1200 IU of the vitamin per day. No correlation was found 
between 25(OH)D levels and dietary intake or supplemental 
use of the vitamin. The group receiving supplemental vitamin 
D, however, showed an increase in 25(OH)D levels at 180 days 
post HSCT, although this difference did not reach statistical 
significance (21.4 ± 10.7 vs. 18.9 ± 12.4 ng/mL, respectively). 
At 30 days post HSCT, serum levels of 25(OH)D were 22.7 
± 10.7 ng/mL, and no statistically significant difference was 
found in comparison to baseline (Figure 2). Sub-optimal 
levels of 25(OH)D were observed in 80% of the patients, with 
38.2% showing vitamin D insufficiency and 41.8% vitamin 
D deficiency. There was no difference in 25(OH)D levels 
Variable  n (%)
Diagnosis
   Non-malignant diseases 44 (67)
   Fanconi anemia 23 (35)
   Severe aplastic anemia 10 (15)
   Wiskott-Aldrich syndrome 6 (9)
   Adrenoleukodystrophy 5 (8)
Malignant diseases 22 (33)
   Acute lymphocytic leukemia 9 (14)
   Acute myeloid leukemia 6 (9)
   Myelodysplasia 4 (6)
   Chronic myeloid leukemia 3 (5)
Type of hematopoietic stem cell transplantation
   Non-related allogeneic 36 (55)
   Related allogeneic 30 (45)
Conditioning
   Without radiotherapy 50 (75)
   With radiotherapy 16 (25)
Table 1 - Clinical characteristics of the patients (n = 66). 
Figure 1 – Serum 25(OH) vitamin D levels in 66 children and 
adolescents before hematopoietic stem cell transplantation in 
comparison with 25 controls matched by gender, age and BMI. The 
plot shows mean levels (dark squares) and standard deviations. 
 
Variable
Patients 
(n = 66)
Controls 
(n = 25)
 
p-value
Age (years) 10.1 ± 4.1 10.2 ± 3.8 1.00
Gender (M:F) 1.4:1 1.5:1 0.87
Weight (kg) 35.6 ± 17.3 39.0 ± 18.6 0.46
BMI (kg/m2) 18.3 ± 3.8 18.6 ± 4.1 0.61
Z-Score BMI/age 0.50 (-4.0 to 3.0) 0.28 (-1.0 to 2.5) 0.76
Lean body mass  
  (kg)
28.7 ± 14.2 31.7 ± 15.2 0.49
Normal vitamin D 19 (29%) 12 (48%) 0.04a
Insufficiency 
  vitamin D
26 (39%) 11 (44%)
Deficiency  
  vitamin D
21 (32%) 2 (8%)
BMI: body mass index. 
a p-value = 0.04 (Fisher’s test for the prevalence of insufficiency, 
deficiency and normal vitamin D levels between patients and 
controls).
Table 2 - Clinical characteristics of the patients before 
hematopoietic stem cell transplantation compared to 
controls.
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vitamin D insufficiency.16 These numbers are a warning of the 
poor vitamin D status of younger populations, which is mainly 
related to the lack of unprotected moderate sun exposure and 
insufficient intake through food and supplements. In addition, 
low 25-OHD levels have been related to adiposity, physical 
activity, and fitness.15 Considering the dietary reference 
intake from The Institute of Medicine (IOM) in 1997, which 
recommends 200 IU of vitamin D per day for individuals 
between 0 and 18 years of age, only 29.7% of the participants 
of our study reported a daily vitamin D intake lower than this 
cut-off.11 However, it is known that this recommendation 
is far from optimal for maintaining adequate serum 25(OH)
D levels.14 If we consider the new dietary reference intake 
published by the IOM in 2010, which recommends at least 400 
IU of vitamin D per day, all participants of our study would be 
classified as having inadequate vitamin D intakes.17 
Given the proposed role of activated vitamin D in immune 
cells, vitamin D status might be of special importance to 
children and adolescents with malignant and non-malignant 
diseases treated with HSCT. In vitro studies report that due 
to its inhibitory effects on T cell proliferation and cytokine 
production, vitamin D plays an important role in controlling the 
immune response that occurs in GVHD.8 In fact, some studies 
have reported an association between low vitamin D levels 
and the presence or progression of GVHD or corticosteroid 
use. Robien et al.4 found a link between 25(OH)D levels after 
HSCT and prednisone and immunosuppressive drug use. 
Kreutz et al.8 studied 48 patients before and after allogeneic 
bone marrow transplantation and detected the lowest levels 
in patients with Grades 3 and 4 of GVHD, in comparison to 
patients without GVHD and Grades 1 and 2 of the disease. 
In our study, we could not detect a statistically significant 
difference in the serum 25(OH)D levels between patients who 
developed GVHD and those who did not, or between those 
who were treated or not treated with corticosteroids. Since 
the sampling size of our study was similar to that of the 
other series, our negative findings may be a result of the high 
prevalence of sub-optimal levels of vitamin D, both before 
and after HSCT. In fact, the mean serum 25(OH)D level was 
approximately 20 ng/mL in the whole group, regardless of 
GVHD or the use of corticosteroids, with 50% of the patients 
exhibiting vitamin D deficiency 180 days after transplantation. 
It is worth mentioning that this high prevalence of vitamin 
D deficiency and the progressive and significant decline of 
25(OH)D levels up to 180 days after HSCT occurred despite the 
protocol of oral vitamin supplementation for these patients in 
our institution.
Vitamin D status has been assessed in adults receiving 
bone marrow transplantation, with many studies looking 
at the correlation with musculoskeletal health. Sproat et al. 
evaluated 58 adult patients after HSCT and found that 89.7% 
of them had low serum 25(OH)D levels.18 Schulte et al.19 
assessed 81 adult patients and found that the majority had 
vitamin D deficiency with secondary hyperparathyroidism, 
and a subsequent reduction in vitamin D levels 28 days after 
the procedure, despite daily vitamin D supplementation. 
Kerschan-Schindl et al.20 found that 25% of 22 adults treated 
with HSCT had vitamin D deficiency six or more years after 
comparing the 15 patients who died to the 51 patients who 
survived (19.6 ± 6.8 vs. 23.1 ± 12.2 ng/mL, respectively).
At 180 days post-HSCT, serum levels of 25(OH)D were 
significantly reduced to 20.9 ± 10.9 ng/mL (p-value = 0.02) in 
relation to the baseline values (Figure 2). Sub-optimal levels 
of 25(OH)D were observed in 69% of the patients, with 18% 
showing vitamin D insufficiency and 51% vitamin D deficiency. 
Dietary vitamin D intake was not significantly different at this 
stage in relation to the baseline values (199.4 ± 135.4 IU/day). 
By multivariate analysis, the variation of 25(OH)D levels at 
180 days after HSCT was tested for dietary intake of vitamin 
D, the use of vitamin D supplementation, weight loss, type 
of conditioning, the use of corticosteroids, the presence of 
GVHD and number of days in the hospital, but no significant 
correlation was found.
Discussion
Serum 25(OH)D is the indicator of vitamin D bioavailability 
in the body.13 It has been recommended that serum levels of 
25(OH)D above 30 ng/mL in children and adults are optimal 
for gaining all the potential health benefits associated with 
vitamin D.13,14 Regular sun exposure and adequate dietary 
intake are essential in meeting these recommendations. 
Dietary sources of the vitamin, however, are limited to milk 
and dairy products, fatty fish and egg yolk, and fortification 
of industrialized foods is still uncommon in many places, 
as in Brazil, thus prompting the need for vitamin D 
supplementation.13 
In the present study, we found a high prevalence of 
vitamin D deficiency and insufficiency both in our children 
and adolescents submitted to HSCT and in our control group, 
with sub-optimal levels observed in 66% of all participants. 
However, this alarming percentage is not exclusive to our 
institution and it has been demonstrated all over the world.3,15 
For instance, the National Health and Nutrition Examination 
Survey 2001-2004, which involved 6275 individuals aged one 
to 21, found that 9% of their population (which represents 7.6 
million US children and adolescents) were vitamin D deficient, 
whereas 61% (50.8 million US children and adolescents) had 
Figure 2 – Serum 25(OH) vitamin D levels in children and 
adolescents before hematopoietic stem cell transplantation (n = 
66) and 30 days (n = 55) and 180 days (n = 51). The plot shows 
mean levels (dark squares) and standard deviations. 
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the procedure, with a correlation between 25(OH)D levels 
and bone mineral density of the lumbar spine. Another study 
assessed adult patients between 12 to 115 months after HSCT, 
and found a correlation between osteoporosis and osteopenia 
with low levels of 25(OH)D and insulin resistance.21 
The literature on serum vitamin D levels in children and 
adolescents on HSCT is scarcer. Duncan et al. assessed the 
prevalence of vitamin D deficiency in 67 children after HSCT 
and found that 80.6% of the group had sub-optimal levels of 
25(OH)D.22 Robien et al.4 followed 44 children and adolescents 
aged one to ten years after HSCT, and observed 34% and 
5% of vitamin D insufficiency and deficiency, respectively. 
Moreover, the authors showed that the lower the vitamin D 
intake (through diet and supplementation), the lower their 
25(OH)D levels were thus suggesting that an intake of 400 to 
600 IU of vitamin D per day is required to maintain adequate 
serum levels. In the current study, all patients received 400 
to 800 IU per day of vitamin D during hospitalization, and 39 
(59%) received vitamin D supplements after discharge for an 
average of 140 days: 50% at doses ranging from 400 to 1200 IU 
and only 9% at a larger daily dose. Accordingly, the prevalence 
of vitamin D deficiency in this study should have been much 
lower as most of the patients received supplements according 
to the current recommendations. Compliance may have been 
a problem and this was not addressed directly in the study. 
Another explanation might be related to alterations in dietary 
intake due to gastrointestinal abnormalities, which are more 
common in these patients, or the use of corticosteroids, 
cyclosporin and anticonvulsants that may also interfere 
with the vitamin D metabolism.4,18,23,24 Lastly, these patients 
received formal recommendations from their doctors for 
reclusion after HSCT, and to avoid any sun exposure in order 
to prevent GVHD and new cases of cancer. Taken together, 
these factors contribute to a high prevalence of vitamin D 
deficiency in children and adolescents treated with HSCT, 
which may have short- and long-term consequences for their 
general health. We believe there is a strong need to review 
the current protocols for preventing and treating vitamin 
D deficiency and insufficiency in these patients, in order to 
achieve adequate and safe vitamin D levels.
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